A case of pyoderma gangrenosum responding to high-dose intravenous immunoglobulin therapy

• Published in: Chinese medical journal Vol. 119; no. 14; pp. 1230 - 1232
• Main Authors: Zhang, Xi-bao, He, Yu-qing, Zhou, Hua, Luo, Quan, Li, Chang-xing
• Format: Journal Article
• Language: English
• Published: China Department of Dermatology, Guangzhou Institute of Dermatology,Guangzhou 510095, China%Department of Dermatology, Shenzhen Dermatological Hospital,Shenzhen 523000, China 20.07.2006
• Subjects: Female; Humans; Immunoglobulins, Intravenous - therapeutic use; Middle Aged; Pyoderma Gangrenosum - drug therapy; Pyoderma Gangrenosum - pathology; Skin - pathology; 免疫球蛋白; 脓皮病; 静脉内治疗; pyoderma gangrenosum; treatment; immunoglobulins,intravenous
• ISSN: 0366-6999; 2542-5641
• DOI: 10.1097/00029330-200607020-00019

Pyoderma gangrenosum （PG） is a rare ulcerative cutaneous condition with distinctivecharacteristics, and the aetiology is not clear yet. PG is commonly associated with inflammatory bowel disease including ulcerative colitis and Crohn＇s disease. This condition is within the spectrum of the neutrophilic dermatoses. The features of PG are not specific histopathologically. Commonly, it is characterized by the presence of marked neutrophilic infiltrates in the dermis. The treatment of PG usually requires systemic corticosteroids or other immunospressive medications, and its course is chronic and relapsing. Some cases are resistant to these treatments. On the other hand, long-term usage of those medications naturally causes serious side effects, and an alternative effective and safe therapy is required to avoid the clinical problems associated with the drugs.